Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening:: A double-blind, randomized, placebo-controlled study

被引:73
作者
De Jong, Floris A.
Kehrer, Diederik F. S.
Mathijssen, Ron H. J.
Creemers, Geert-Jan
De Bruijn, Peter
van Schaik, Ron H. N.
Planting, Andre S. Th.
Van der Gaast, Ate
Eskens, Ferry A. L. M.
Janssen, Jos Th. P.
Ruit, Jan B.
Verweij, Jaap
Sparreboom, Alex
De Jonge, Maja J. A.
机构
[1] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands
[2] Ijsseland Hosp, Dept Internal Med, Capelle aan den IJssel, Netherlands
[3] Catharina Hosp, Dept Internal Med, Eindhoven, Netherlands
[4] Erasmus Univ, Med Ctr, Dept Med Oncol, NL-3000 DR Rotterdam, Netherlands
[5] Franciscus Hosp, Dept Internal Med, Roosendaal, Netherlands
[6] Vlietland Hosp, Dept Internal Med, Vlaardingen, Netherlands
关键词
diarrhea; irinotecan; neomycin; pharmacokinetics; pharmacogenetics; UGT1A1;
D O I
10.1634/theoncologist.11-8-944
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Delayed-type diarrhea is a common side effect of irinotecan and is associated with a bacterial-mediated formation of the active irinotecan metabolite SN-38 from its glucuronide conjugate in the intestine. Based on a pilot study, we hypothesized that concomitant administration of the antibiotic neomycin would diminish exposure of the gut to SN-38 and ameliorate the incidence and severity of diarrhea. Patients and Methods. Patients were treated with irinotecan in a multicenter, double-blind, randomized, placebo-controlled trial. Eligible patients received irinotecan (350 mg/m(2) once every 3 weeks) combined with neomycin (660 mg three times daily for three consecutive days, starting 2 days before chemotherapy) or combined with placebo. Blood samples were obtained for additional pharmacokinetic and pharmacogenetic analyses. Results. Sixty-two patients were evaluable for the toxicity analysis. Baseline patient characteristics, systemic SN-38 exposure, and UGT1AI*28 genotype status (i.e., an additional TA repeat in the promoter region of uridine diphosphate-glucuronosyltransferase isoform 1A1) were similar in both arms. Although distribution, severity, and duration of delayed-type diarrhea did not differ significantly between arms, grade 3 diarrhea tended to be less frequent in the neomycin arm. The presence of at least one UGT1A1*28 allele was strongly related to the incidence of grade 2-3 diarrhea. In the neomycin arm, grade 2 nausea was significantly more common. Conclusion. Our results do not suggest a major role for neomycin as prophylaxis for irinotecan-induced delayed-type diarrhea. It is suggested that the UGT1A1*28 genotype status could be used as a screening tool for a priori prevention of irinotecan-induced delayed-type diarrhea.
引用
收藏
页码:944 / 954
页数:11
相关论文
共 64 条
  • [1] IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
    ABIGERGES, D
    ARMAND, JP
    CHABOT, GG
    DACOSTA, L
    FADEL, E
    COTE, C
    HERAIT, P
    GANDIA, D
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) : 446 - 449
  • [2] New approaches to prevent intestinal toxicity of irinotecan-based regimens
    Alimonti, A
    Gelibter, A
    Pavese, I
    Satta, F
    Cognetti, F
    Ferretti, G
    Rasio, D
    Vecchione, A
    Di Palma, M
    [J]. CANCER TREATMENT REVIEWS, 2004, 30 (06) : 555 - 562
  • [3] Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer
    Alimonti, A
    Satta, F
    Pavese, I
    Burattini, E
    Zoffoli, V
    Vecchione, A
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (05) : 805 - 806
  • [4] Ando Y, 2000, CANCER RES, V60, P6921
  • [5] UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
    Ando, Y
    Saka, H
    Asai, G
    Sugiura, S
    Shimokata, K
    Kamataki, T
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (08) : 845 - 847
  • [6] Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    Benson, AB
    Ajani, JA
    Catalano, RB
    Engelking, C
    Kornblau, SM
    Martenson, JA
    McCallum, R
    Mitchell, EP
    O'Dorisio, TM
    Vokes, EE
    Wadler, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2918 - 2926
  • [7] THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME
    BOSMA, PJ
    CHOWDHURY, JR
    BAKKER, C
    GANTLA, S
    DEBOER, A
    OOSTRA, BA
    LINDHOUT, D
    TYTGAT, GNJ
    JANSEN, PLM
    ELFERINK, RPJO
    CHOWDHURY, NR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) : 1171 - 1175
  • [8] Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803
    Bouche, O
    Raoul, JL
    Bonnetain, F
    Giovannini, M
    Etienne, PL
    Lledo, G
    Arsène, D
    Paitel, JF
    Guérin-Meyer, V
    Mitry, E
    Buecher, B
    Kaminsky, MC
    Seitz, JF
    Rougier, P
    Bedenne, L
    Milan, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) : 4319 - 4328
  • [9] Castellanos C, 2003, P AN M AM SOC CLIN, V22, P162
  • [10] Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer
    Chester, JD
    Joel, SP
    Cheeseman, SL
    Hall, GD
    Braun, MS
    Perry, J
    Davis, T
    Button, CJ
    Seymour, MT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 1125 - 1132